A comprehensive view of Pharmaxis Ltd.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.
Aptar Pharma acquires worldwide license for Orbital Dry Powder Inhaler from Pharmaxis for undisclosed amount; high payload Orbital technology delivers up to 400 mg of powders in divided doses without the need to reload
Published: August 10, 2022 by AptarGroup Inc.
Ask us about our Health Care Sector market view